79 results about "Antiviral therapy" patented technology

A system for the hypothermic transport of biological samples, such as tissues, organs, or body fluids. The system includes an antimicrobial treatment mechanism to inactivate microbes flushed from the biological sample by preservation fluid flowed therethrough. The self-purging preservation apparatus is placed in an insulated transport container having a cooling medium. When assembled, the system allows for transport of biological samples for extended periods of time at a stable temperature while simultaneously treating microbial infections to prevent transmission between a donor and a recipient.

The invention discloses a computer device and a computer readable storage medium for evaluating the immune reconstitution state of an HIV infected person after ART. Belongs to the field of computer information. The technical problem to be solved by the invention is how to evaluate the immune reconstruction state of an HIV infected person after ART. The invention provides a computer program stored in a memory in a computer device. The computer program comprises the following steps: S1, receiving sample data, namely the proportion of the number of cells expressing PD-1 in CD8 + T cells of peripheral blood mononuclear cells of an HIV infected subject after ART and the proportion of the number of cells expressing at least one of the following five factors: CD38, HLA-DR, CD57, PERFORIN and CD107A; s2, obtaining a predicted value Y from the sample data through a model formula, and outputting an immune reconstruction condition according to the predicted value Y and a pre-judgment condition; the method can accurately and efficiently determine whether the immune reconstruction state of the HIV infected person subjected to antiviral treatment is good or not.

AM580 and structurally related compounds have been found to be useful in treating infection by a wide range of RNA and DNA viruses, and also in reducing associated inflammation. This activity is independent of RAR-α signaling, and is not a result of activation of the hosts innate immune response. Broad antiviral activity of AM580 and structurally related compounds is a due to modulation of lipogenesis so as to correct disregulation of this pathway in virus-infected cells, via inhibition of nSREPBP.

The invention discloses a method and system for analyzing next-generation sequencing data and application. The specific detection of the transcriptional activity of the cccDNA is realized by utilizing the two characteristic sequences, a new analysis method is provided for evaluating the antiviral treatment effect and judging functional cure, and individualized treatment and new drug research and development can be guided. In addition, the method is also suitable for designing specific quantitative PCR probes and primers, the cccDNA transcriptional level is evaluated by detecting characteristic fragments, and a more convenient detection means is provided for clinical laboratories.

The present invention relates to a nanobody against human adenovirus type 4 Hexon protein, which nanobody has a unique CDR region, can bind to adenovirus type 4 Hexon protein with high affinity, and can neutralize adenovirus type 4 pseudovirus with high neutralizing activity in a virus neutralization test, and to the use thereof in antiviral therapy. The invention also provides application of the nano antibody in preparation of a medicine for treating and / or preventing human type 4 adenovirus infectious diseases and a diagnostic kit.

The application discloses a primer group and a method for detecting HIV-1 RNA protease and reverse transcriptase region drug resistance site mutation. The detection method can be applied to protease and reverse transcriptase drug resistance detection of HIV-1 RNA including low-concentration HIV-1 RNA by optimizing a drug resistance reaction system, an amplification program and primer sequences. The detection method can use serum, plasma, semen, urine, cerebrospinal fluid and other human body fluids as samples, adopts a specific primer group, amplifies HIV-1 protease and reverse transcriptase region sequences through a nested PCR method, and determines the amplified sequences through a Sanger sequencing method to analyze drug resistance related gene mutations, so that the HIV-1 RNA protease and reverse transcriptase region drug resistance detection efficiency is greatly improved. Whether the patient is resistant to a specific drug and the degree of drug resistance are judged by using a genotype drug resistance interpretation system, so as to provide a reference basis for the patient to formulate a first-line antiviral treatment, a second-line treatment scheme, a pre / post-exposure prevention drug scheme and a measure for reducing drug resistance.

Disclosed herein is a delivery vehicle based on DNA-inspired Janus based nanotubes (JBNTs) for anti-viral treatment. The nanoparticles (NPs) are based the JBNTs conjugated with targeting moieties such as small molecules, aptamers, and peptides.

The present application belongs to the field of genetic engineering and biological medicine technology, and particularly relates to a biomaterial for regulating HTRA1 gene expression and application thereof in antiviral. Specifically, the present application finds that inhibiting HTRA1 gene can significantly promote replication of H13N2 subtype influenza virus, thereby promoting infection of H13N2 subtype influenza virus, while overexpression of HTRA1 can effectively inhibit replication of H13N2 subtype influenza virus, reduce virus titer, and thus improve the ability to resist influenza virus infection, so that the HTRA1 gene can be used as a key target for regulating replication of H13N2 subtype influenza virus, and thus has good practical application value.

The present application relates to the development and application of a kind of nanobody 2A5 for neutralizing broad-spectrum respiratory syncytial virus, and specifically relates to a kind of nanobody, which includes CDR1 as shown in SEQ ID NO:3, CDR2 as shown in SEQ ID NO:4, and CDR3 as shown in SEQ ID NO:5.The nanobody provided by the present application has the characteristics of high affinity and high neutralization, can effectively neutralize respiratory syncytial virus A2 and B strain, and the neutralization capacity is better than that of marketed antibody Nirsevimab.Therefore, the nanobody has great potential for further development as a candidate for preventing and treating respiratory syncytial virus, and also provides a scientific basis for the development of other antiviral therapies for respiratory syncytial virus.

Compositions of nucleases in formulations with dendrimers are used in pharmaceutically effective dosages as therapeutics for covid-19 and a broad spectrum of viruses in various embodiments. When cationized nucleases are mixed and / or complexed with a dendrimer, an unexpected positive dendrimer effect is manifest. This positive dendrimer effect is shown to be highly effective for catalyzing anti-viral RNase properties. In various embodiments compositions of cationized nucleases in combination with a dendrimer demonstrated this synergistic amplification of anti-viral effectiveness and are used in pharmaceutically effective dosages as therapeutics against covid-19 and a broad spectrum of viruses. An exemplar formulation which exhibits a positive dendrimer effect is cationized RNase A mixed and / or complexed with gen 2 PAMAM dendrimer.

Compositions of nucleases in formulations with dendrimers are used in pharmaceutically effective dosages as therapeutics for covid-19 and a broad spectrum of viruses in various embodiments. When cationized nucleases are mixed and / or complexed with a dendrimer, an unexpected positive dendrimer effect is manifest. This positive dendrimer effect is shown to be highly effective for catalyzing anti-viral RNase properties. In various embodiments compositions of cationized nucleases in combination with a dendrimer demonstrated this synergistic amplification of anti-viral effectiveness and are used in pharmaceutically effective dosages as therapeutics against covid-19 and a broad spectrum of viruses. An exemplar formulation which exhibits a positive dendrimer effect is cationized RNase A mixed and / or complexed with gen 2 PAMAM dendrimer.

The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and / or treatment of infection by HIV, and in the treatment of AIDS and / or ARC.

The present invention discloses an artificial virus receptor and its application, which belongs to the field of biotechnology. The artificial virus receptor of the present invention includes modules A, B, C, D, E, F, G, and H from the amino terminus to the carboxyl terminus. Module A is a signal peptide of type I membrane protein; module B is a customized virus binding domain for capturing target viruses; modules C and E are linkers; module D is a spacer region for forming the skeleton of a customized artificial virus receptor to maintain a certain length outside the cell; module F is a transmembrane domain for realizing cell surface display of the artificial virus receptor; module G is an intracellular domain, which has the function of maintaining the stability of the artificial virus receptor; module H is a tag protein. The present invention paves the way for the rapid construction of in vitro and in vivo infection systems of viruses that are difficult to culture, especially high-risk coronaviruses, and for downstream prospective research, which will help to further advance the life cycle research of many difficult-to-culture viruses and promote the development of antiviral treatments and vaccines.

The invention discloses a monoclonal antibody and a single-chain antibody of HBV preS1, an HBV specific CAR-T cell constructed by the monoclonal antibody and the single-chain antibody and application of the HBV specific CAR-T cell. The monoclonal antibodies 3A1, 6B12 and 8G6 of the HBV preS1 can be combined with HBV expression hepatocytes. A light chain variable region and a heavy chain variable region of a monoclonal antibody are connected through a GS linker to obtain a single-chain antibody, a chimeric antigen receptor (CAR) is constructed, and the chimeric antigen receptor (CAR) is transfected to a T cell through lentivirus, so that the preS1 specific CAR-T cell is constructed. In-vitro experiments prove that the successfully constructed CAR-T cells can be successfully activated by liver cells expressing HBV and have a killing effect on the liver cells expressing HBV. The constructed CAR-T cell taking the preS1 as the target provides a new possibility for constructing a therapeutic CAR-T cell with stronger lethality and activity, and has important significance for exploring targeted immunoregulation antiviral therapy.

The invention relates to an application of SLC15A3 in preparation of an anti-dengue virus drug, and discovers that a novel antiviral protein SLC15A3 has a novel application of efficiently targeting a dengue virus non-structural protein NS4A so as to inhibit the proliferation of a dengue virus in a host cell. The invention develops a new field of clinical application of the humanized antiviral protein in the field of antiviral prevention and treatment, so that a new thought and direction are provided for drug development of targeted dengue virus non-structural protein NS4A, a scientific basis is provided for development of anti-dengue virus drugs, and a new thought is provided for clinical antiviral treatment.

Methods and kits for the rapid detection of active coronavirus infection by specifically targeting the negative-sense RNA produced during viral replication. The method utilizes nucleic acid amplification techniques, such as RT-PCR and qPCR, with primers specific to the negative strand, which serves as a marker for active viral replication. The present disclosure also encompasses a rapid, user-friendly lateral flow test based on CRISPR-Cas13a technology that targets the negative-sense viral RNA. This LFT employs guide RNAs specific to the negative strand and a reporter system to visually indicate the presence of actively replicating viruses, thereby distinguishing active infections from the presence of non-replicating viral remnants. The methods and kits offer a more accurate means of determining infectivity, guiding public health measures, and monitoring antiviral therapies.

The invention relates to an HTNV host binding protein screening system established based on a CRISPR / dCas13 system and application of the HTNV host binding protein screening system. The screening system comprises dCas13 protein and crRNA. The dCas13 protein is a dCasRx protein, and the dCasRx protein is a The crRNA comprises crRNA2 and crRNA7, and the sequences of the crRNA2 and the crRNA7 are respectively SEQ ID NO: 2 and SEQ ID NO: 7. The screening system for screening the HTNV-S-RNA host binding protein is established by utilizing a CRISPR / dCasRx system, the feasibility of the screening system is verified through experiments, meanwhile, the screened candidate protein is verified to have obvious influence on HTNV replication, and a new thought is provided for researching an HTNV virus replication mechanism and discovering a new antiviral treatment target.

The invention provides an mRNA molecule of IFN-omega, a recombinant expression vector, lipid nanoparticles and application, the mRNA molecule of IFN-omega comprises an ORF sequence for coding IFN-omega protein, and the nucleotide sequence of the ORF sequence is as shown in SEQ ID NO: 7. The invention develops a novel antiviral treatment scheme for expressing IFN-omega in vivo by using mRNA-LNP, so that the treatment effect of resisting FCV and FHV-1 is improved, the bioavailability is improved, the safety risk is reduced, and the application has important clinical significance and application value.

The application provides a plurality of new therapeutic peptides, which are designed based on the heptad repeat region of a viral spike fusion protein (such as SARS-Cov2, MERS-CoV, or HCov-OC43) or a heptad repeat region in a paramyxovirus (such as Measles, Nipah, or HPIV3) ), new therapeutic conjugates that comprising these therapeutic peptides, and methods of using the therapeutic peptide conjugates for the treatment of a condition or disease associated with a viral infection.

The present invention offers a new approach for highly multiplexed, programmable antiviral therapies that directly target viral RNA, and can be flexibly adapted to target novel viruses or emerging outbreak pathogens. Class 2, type VI CRISPR system-based therapies can be used in combination with existing antiviral compounds for viruses where such compounds exist, either by increasing their efficacy or by preventing the evolution of specific drug resistance mutations. Perhaps most excitingly, if a virus evolves resistance to a specific guide RNA sequence, it is easy to switch to a different guide RNA sequence, or to design a new guide sequence to target the new mutation. Such approaches should prevent the widespread development of resistance to Class 2, type VI CRISPR system-based therapies.

The present disclosure provides methods and pharmaceutical formulations for the treatment and prophylaxis of a viral infection unresponsive to treatment with one or more first antiviral therapy using a cyclic urea thiozole compound.

Formulas for use in enhancing the transduction efficiency of lentiviral vector (LV) particles into various target cells are disclosed herein. For example, a formulation for use in enhancing the transduction of paramyxovirus pseudotype lentiviral vector particles into target cells may comprise a cell-permeable peptide (CPP) comprising at least one of Vectofusion-1 or LAH4-C; and poloxamer 407, wherein the concentration of poloxamer 407 is greater than or equal to the concentration of CPP. Additionally, a method of using such formulations to enhance the transduction of LV particles, including particularly in vivo transduction, is disclosed herein.

The invention provides a human monoclonal antibody E2DG for resisting type 4 adenovirus. The neutralizing antibody for resisting the 4-type adenovirus provided by the invention can be specifically combined with the 4-type adenovirus, and has very high affinity activity and very strong neutralizing activity at low concentration. The invention also provides application of the antibody in preparation of medicines for treating and / or preventing type 4 adenovirus diseases, and a detection kit containing the antibody.

The present invention relates to a nanobody directed against the human adenovirus type 4 Hexon protein and its use in antiviral therapy. The nanobody has a unique CDR region, can bind to the adenovirus type 4 Hexon protein with high affinity, and can neutralize adenovirus type 4 pseudovirus with high neutralizing activity in virus neutralization assays. The present invention also provides the use of the nanobody in the preparation of a drug for treating and / or preventing diseases caused by human adenovirus type 4, as well as a diagnostic kit.

The application provides a plurality of new therapeutic peptides, which are designed based on the heptad repeat region of a viral spike fusion protein (such as SARS-Cov2, MERS-CoV, or HCov-OC43) or a heptad repeat region in a paramyxovirus (such as Measles, Nipah, or HPIV3) ), new therapeutic conjugates that comprising these therapeutic peptides, and methods of using the therapeutic peptide conjugates for the treatment of a condition or disease associated with a viral infection.

The application provides a plurality of new therapeutic peptides, which are designed based on the heptad repeat region of a viral spike fusion protein (such as SARS-Cov2, MERS-CoV, or HCov-OC43) or a heptad repeat region in a paramyxovirus (such as Measles, Nipah, or HPIV3)), new therapeutic conjugates that comprising these therapeutic peptides, and methods of using the therapeutic peptide conjugates for the treatment of a condition or disease associated with a viral infection.

The present disclosure provides methods and pharmaceutical formulations for the treatment and prophylaxis of a viral infection unresponsive to treatment with one or more first antiviral therapy using a cyclic urea thiozole compound.

The present invention relates to chlorophyll protein analogs and pharmaceutically acceptable salts thereof, and to compositions comprising chlorophyll protein analogs and pharmaceutically acceptable salts thereof. The chlorophyll protein analogs and pharmaceutically acceptable salts thereof are suitable for use in photodynamic therapy, cytoluminescence therapy and photodynamic diagnostics, for example for the treatment or detection of tumors or for antiviral therapy. The invention also relates to the use of the chlorophyll protein analogs and pharmaceutically acceptable salts thereof in the manufacture of phototherapeutic or photodiagnostic agents, and to methods of photodynamic therapy, cytoluminescence therapy or photodynamic diagnosis, for example for the treatment or detection of tumors or for antiviral therapy. # imgabs0 #

Provided is use of a magnetoelectrically driven magnetostrictive piezoelectric nanoparticle in antiviral therapy. The magnetostrictive piezoelectric nanoparticle comprises a shell structure with piezoelectric properties and a core structure with magnetoelectric response properties. The magnetostrictive piezoelectric nanoparticle, by means of up-regulating multiple immunomodulatory pathways, effectively enhances the expression of type I interferon and a host's innate immune response, ultimately inhibiting the viral activity, ameliorating hepatic and pulmonary tissue damage, and improving the survival rates. The magnetostrictive piezoelectric nanoparticle has the advantages such as high controllability, deep penetration, and non-invasiveness, and offers broad application prospects in the antiviral field.

The invention belongs to the technical field of antiviral drugs, and in particular relates to a novel application of procyanidine A1 in preparation of a drug for inhibiting porcine epidemic diarrhea virus (PEDV). The porcine epidemic diarrhea (PED) is a high-contact intestinal infectious disease caused by the PEDV (porcine epidemic diarrhea virus), so that huge economic loss is caused to the global pig breeding industry. Currently, PEDV serving as an RNA virus is extremely easy to mutate, so that the protection effect of the existing vaccine is limited, and a special-effect antiviral therapeutic drug is lacked clinically. It is found for the first time that the natural compound procyanidine A1 has remarkable inhibitory activity on the porcine epidemic diarrhea virus and can effectively inhibit replication of the virus in cells. In-vitro experiments prove that the procyanidine A1 has no obvious toxicity to cells at an effective antiviral concentration and has high safety. The invention provides a brand new and effective drug choice for prevention and control of PEDV, and has important application value and wide market prospect.